title: Immunopharmacological in vitro effects of Eleutherococcus senticosus extracts.
abstract: The objective of these investigations was to further elucidate the immunopharmacological profile of fluid extracts of Eleutherococcus senticosus and to identify the specific role of its characteristic eleutherosides B and E. An ethanolic dry extract of Eleutherococcus senticosus was used as starting material for the isolation of the eleutherosides B and E. Immunopharmacological studies included expression of major histocompatibility complex class I and II molecules by rat bone marrow-derived mononuclear phagocytes, human lymphocyte marker flow cytometry, and in vitro testing of human lymphocyte functions. In contrast to the isolated eleutherosides B and eleutherosides E and the re-mixed eleutherosides B and E, the whole ethanolic fluid extract of Eleutherococcus senticosus was able to induce and enhance interleukin-1 and interleukin-6 but not interleukin-2 production in vitro. The effective concentration of the whole ethanolic extract ranged from 1.0-0.1 mg/ml for the enhancement of interleuking-1 alpha production and 1.0-0.03 mg/ml for the enhancement of interleukin-6 production. It is concluded that the observed enhancing immunopharmacological activities on acute phase response mediators are best exhibited by the induction with whole ethanolic extracts whereas the species-specific and characteristic eleutherosides B and E are not associated with these activities.
authors.affiliation: Boehringer Ingelheim, Biberach/Riss, Germany. gerhard.steinmann@bc.boehringer-ingelheim.com
authors.forename: G G
authors.initials: GG
authors.lastname: Steinmann
authors.forename: A
authors.initials: A
authors.lastname: Esperester
authors.forename: P
authors.initials: P
authors.lastname: Joller
mesh_terms: D000276:Adjuvants, Immunologic / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D005805:Genes, MHC Class I; D005802:Genes, MHC Class II; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D017705:Lignans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009000:Monocytes / Q000187:drug effects; D019798:Neopterin / Q000096:biosynthesis; D010666:Phenylpropionates; D010946:Plants, Medicinal / Q000737:chemistry*; D051381:Rats; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet; D001613:beta 2-Microglobulin / Q000096:biosynthesis
chemical_list: D000276:Adjuvants, Immunologic; D017252:CD3 Complex; D016207:Cytokines; D005960:Glucosides; D006684:HLA-DR Antigens; D017705:Lignans; D010666:Phenylpropionates; D001613:beta 2-Microglobulin; D019798:Neopterin; C421885:eleutheroside E; C028305:syringin